Zydus Lifesciences To Pay $120 Million To Astellas To Settle Patent Litigation

Zydus Pharmaceuticals USA, Inc USA, a wholly owned subsidiary of the company, has entered into a settlement agreement with Astellas in relation to its drug Myrbetriq.